Eupraxia Pharmaceuticals (EPRX) Cash from Operations (2023 - 2026)
Eupraxia Pharmaceuticals' (EPRX) quarterly Cash from Operations came in at 10146747.0 in Q1 2026, down 69.03% year-on-year from 32758850.41 in Q1 2025, and down 4.31% on a QoQ basis from 9727337.0 in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Cash from Operations (2023 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has 4 years of Cash from Operations data on file, last reported at 10146747.0 in Q1 2026.
- On a quarterly basis, Cash from Operations fell 69.03% year-over-year to 10146747.0 in Q1 2026; TTM through Mar 2026 was 32695894.0, a 9.49% decrease from a year earlier, with the FY2025 full-year figure at 28552218.0, up 4.81% from the prior year.
- Cash from Operations for Q1 2026 stood at 10146747.0, down from 9727337.0 in the prior quarter.
- Over the last five years, Cash from Operations for EPRX reached as high as 4271984.0 in Q2 2023 and fell as low as 10189609.0 in Q3 2024.
- Historically, Cash from Operations has averaged 6880159.62 across 4 years, with a median of 6003071.0 in 2025.
- Across the five-year window, Cash from Operations slumped 80.15% in 2024 and jumped 55.77% in 2025, its largest moves.
- Year by year, Cash from Operations stood at 5964756.0 in 2023, then retreated by 0.13% to 5972330.0 in 2024, then tumbled by 62.87% to 9727337.0 in 2025, then retreated by 4.31% to 10146747.0 in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were 10146747.0 in Q1 2026, 9727337.0 in Q4 2025, and 4506556.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Eupraxia Pharmaceuticals | 357.29 Mn | 355.69 Mn | - | -10.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.15 Mn |
| Mar 31, 2026 | -10.15 Mn |
| Dec 31, 2025 | -9.73 Mn |
| Dec 31, 2025 | -9.73 Mn |
| Sep 30, 2025 | -4.51 Mn |
| Sep 30, 2025 | -4.51 Mn |
| Jun 30, 2025 | -8.32 Mn |
| Jun 30, 2025 | -8.32 Mn |
| Mar 31, 2025 | -6.00 Mn |
| Mar 31, 2025 | -6.00 Mn |
| Dec 31, 2024 | -5.97 Mn |
| Dec 31, 2024 | -5.97 Mn |
| Sep 30, 2024 | -10.19 Mn |
| Sep 30, 2024 | -10.19 Mn |
| Jun 30, 2024 | -7.70 Mn |
| Jun 30, 2024 | -7.70 Mn |
| Mar 31, 2024 | -6.14 Mn |
| Mar 31, 2024 | -6.14 Mn |
| Dec 31, 2023 | -5.96 Mn |
| Dec 31, 2023 | -5.96 Mn |